Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
VERACYTE, INC. | President, CLIA U.S. | Stock Option (right to buy) | 103K | $2.74M | $26.55 | Mar 3, 2022 | Direct |
VERACYTE, INC. | President, CLIA U.S. | Common Stock | 77K | $2.04M | $26.54 | Mar 3, 2022 | Direct |
Azenta, Inc. | Director | Common | 6.07K | $400K | $65.93 | Feb 12, 2024 | Direct |
Azenta, Inc. | Director | Common Stock | 3.6K | $209K | $57.96 | Feb 13, 2023 | Direct |
EXAGEN INC. | Director | Stock Option(right to buy) | 13.5K | Jun 10, 2024 | Direct | ||
ARENA PHARMACEUTICALS INC | Director | Common Stock | 0 | $98.51 | Mar 11, 2022 | Direct | |
ARENA PHARMACEUTICALS INC | Director | Stock Option (right to buy) | 0 | Mar 11, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
XGN | EXAGEN INC. | Jun 10, 2024 | 1 | $0 | 4 | Jun 12, 2024 | Director |
AZTA | Azenta, Inc. | Feb 12, 2024 | 1 | -$163K | 4 | Feb 13, 2024 | Director |
XGN | EXAGEN INC. | Jun 15, 2023 | 1 | $0 | 4 | Jun 20, 2023 | Executive Chairperson, Director |
AZTA | Azenta, Inc. | Feb 13, 2023 | 1 | $0 | 4 | Feb 15, 2023 | Director |
AZTA | Azenta, Inc. | Feb 3, 2023 | 0 | $0 | 3 | Feb 7, 2023 | Director |
XGN | EXAGEN INC. | Jun 16, 2022 | 1 | $0 | 4 | Jun 21, 2022 | Director |
ARNA | ARENA PHARMACEUTICALS INC | Mar 11, 2022 | 8 | $0 | 4 | Mar 11, 2022 | Director |
VCYT | VERACYTE, INC. | Mar 3, 2022 | 2 | $0 | 4 | Mar 7, 2022 | President, CLIA U.S. |
VCYT | VERACYTE, INC. | Mar 2, 2022 | 1 | -$298K | 4 | Mar 4, 2022 | President, CLIA U.S. |
VCYT | VERACYTE, INC. | Jan 6, 2022 | 0 | $0 | 3 | Jan 13, 2022 | President, CLIA U.S. |
XGN | EXAGEN INC. | Jun 17, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director |
ARNA | ARENA PHARMACEUTICALS INC | Jun 11, 2021 | 2 | $0 | 4 | Jun 15, 2021 | Director |